Roche

DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.

We're a digital healthcare company on a mission to enhance patients outcome by helping doctors and companies make better decisions through the generation of reliable synthetic data and by developing decision support systems

Soteria is developing a next generation of conditionally active bispecific t-cell engaging antibodies to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITE™ platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

GenMark Diagnostics, Inc. (GenMark) is a molecular diagnostics company focused on developing and commercializing its eSensor detection technology. The Company’s electrochemical technology enables detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA), and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its eSensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.

Enthera S.r.l. is a biotechnology company based in Milan, Italy, founded in 2016. The company focuses on developing innovative therapeutic approaches for diabetes and related gastrointestinal complications, particularly enteropathy, along with other intestinal disorders that share similar biological pathways. Enthera operates a monoclonal antibody discovery platform to create first-in-class biologics aimed at addressing these underserved conditions. The company was established as a subsidiary of BiovelocITA S.r.l. and was founded in collaboration with scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio. The name "Enthera" is derived from a combination of the terms "entero," referring to the intestine, and "therapy," reflecting its commitment to developing targeted treatments.

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being.

Palladio Biosciences, Inc. is a clinical-stage biotechnology company focused on developing transformative medicines for orphan diseases affecting the kidneys. Founded in 2015 and based in Horsham, Pennsylvania, the company is recognized for its work on Lixivaptan, a selective vasopressin V2 receptor antagonist aimed at treating polycystic kidney disease, a serious genetic condition. Palladio Biosciences aims to address unmet medical needs in the field of renal diseases through its innovative therapeutic solutions.

Inflazome Ltd. is a biotechnology company focused on developing orally available drugs that target inflammasomes to treat a range of inflammatory diseases. Founded in 2016 and headquartered in Dublin, Ireland, Inflazome aims to address unmet clinical needs in conditions such as orphan diseases, neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain types of cancer. By blocking inflammasome signals, the company's therapeutics aim to tackle the underlying causes of inflammation, offering targeted treatment options for conditions including cardiovascular issues, arthritis, and gastrointestinal disorders. Inflazome operates as a subsidiary of Roche Holding AG, with additional offices in the United Kingdom.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

Pandion Operations, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its lead product candidate, PT101, is an engineered variant of interleukin-2 (IL-2) currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions. Other product candidates include PT627, a systemic PD-1 agonist in preclinical studies; PT001, a bifunctional molecule designed to achieve tissue-selective immunomodulation in the gastrointestinal tract; and PT002, which combines an IL-2 mutein with a tether module for similar localized effects. The company collaborates with Astellas Pharma Inc. to develop immunomodulators aimed at autoimmune diseases specifically affecting the pancreas. Headquartered in Watertown, Massachusetts, Pandion Operations seeks to create innovative therapies that can provide durable and tissue-specific treatment options for patients suffering from these conditions.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2018 and based in South San Francisco, California. The company specializes in developing novel therapeutics aimed at addressing unmet medical needs in viral and liver diseases. Its lead candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for chronic hepatitis B (CHB). In addition to this, Aligos is advancing several other drug candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist targeting non-alcoholic steatohepatitis (NASH). The company leverages its extensive expertise in liver disease and viral hepatitis to develop targeted antiviral therapies, positioning itself as a leader in this therapeutic area.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Promedior, Inc. a clinical-stage biotechnology company, develops therapeutics to treat rare fibrotic diseases, such as myelofibrosis and idiopathic pulmonary fibrosis; and retinal fibrovascular diseases, such as age related macular degeneration and diabetic retinopathy. Its portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein (rhPTX-2) formulated for intravenous injection; and PRM-167, a variant of rhPTX-2 developed for intravitreal delivery in retinal fibrovascular diseases. Promedior, Inc. was formerly known as Fibrotix, Inc. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of February 13, 2020, Promedior, Inc. operates as a subsidiary of Roche Holding AG.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

Spark Therapeutics, Inc. is dedicated to developing gene therapy products aimed at treating debilitating genetic diseases. The company is known for LUXTURNA, a treatment for patients with biallelic RPE65 mutation-associated retinal dystrophy, and has an extensive pipeline that includes candidates like SPK-8011 and SPK-8016 for hemophilia, SPK-7001 for choroideremia, and SPK-9001 for hemophilia B. Additionally, Spark is exploring liver-directed gene therapies such as SPK-3006 for Pompe disease and has programs targeting neurodegenerative diseases, including Huntington's disease and a form of Batten disease. Spark Therapeutics also engages in collaborations, notably with Pfizer for the SPK-FIX program for hemophilia B, and has a licensing agreement with Novartis for the commercialization of LUXTURNA outside the United States. Established in 2013 and based in Philadelphia, Spark Therapeutics operates as a subsidiary of Roche Holding AG and leverages a proprietary manufacturing platform to support its clinical studies across various therapeutic areas.

Good Therapeutics develops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed. It is an early-stage biotechnology company based in Seattle, Washington. They are developing context-dependent protein drugs that sense biomarkers and respond with therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy. Their core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. They are currently focused on immuno-oncology applications of the technology.

Black Diamond Therapeutics is a precision oncology medicine company focused on discovering and developing small molecule, tumor-agnostic therapies. The company's lead product candidate, BDTX-189, is designed to inhibit specific mutations in ErbB kinases, including the epidermal growth factor receptor. Additionally, Black Diamond is advancing a pipeline of allosteric-EGFR mutation inhibitors and other early-stage programs targeting allosteric mutations in kinases associated with cancer and rare genetic diseases. The company employs a technology platform known as Mutation-Allostery-Pharmacology, which aims to address undrugged mutations in patients with genetically defined cancers. Founded in 2014 and based in Cambridge, Massachusetts, Black Diamond Therapeutics was previously known as ASET Therapeutics until its rebranding in 2018.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Tusk Therapeutics Ltd develops therapeutic antibodies for the treatment of cancer. The company develops immuno-oncology drugs that work for the depletion of regulatory T-cells (Tregs). The company's products include CD25, a Treg depleting agent and CD38, an immune checkpoint which inhibits immunosuppressive cells. The company was founded in 2014 and is based in Stevenage, United Kingdom. As of September 28, 2018, Tusk Therapeutics Ltd operates as a subsidiary of F. Hoffmann-La Roche Ltd.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

Care Innovations provides technology-based healthcare management services designed to connect people to care givers. The company's services include collecting, aggregating and analyzing data and provide informed and actionable insights into connecting providers, payers, caregivers and consumers and bringing the care continuum to the home, enabling people to live independently.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

CiVi Biopharma is a clinical stage research and development biotechnology company whose mission is to create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company has multiple assets in various stages of development including Intravenous Iloprost in Phase 3 trials for treatment of Systemic Sclerosis.

Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise. Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

IDEAYA Biosciences is an oncology-focused biotechnology company based in South San Francisco, California, dedicated to the discovery and development of targeted therapeutics for genetically defined patient populations. The company specializes in precision medicine using molecular diagnostics and synthetic lethality approaches to address cancer treatment. Its lead product candidate, IDE196, is a protein kinase C inhibitor currently undergoing Phase 1/2 clinical trials for cancers associated with GNAQ or GNA11 gene mutations. IDEAYA's preclinical pipeline includes programs targeting various mechanisms related to DNA damage and repair, such as MAT2A for tumors with MTAP deletions, Pol-theta for homologous recombination deficiency, and PARG for BRCA2 mutation context. The company collaborates with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase, while also engaging in partnerships for clinical trials with Pfizer and GlaxoSmithKline. Founded in 2015, IDEAYA aims to advance innovative therapies for enhancing immunotherapy responses and improving patient outcomes in oncology.

Flatiron Health, Inc. is a healthcare technology company that specializes in oncology, focusing on enhancing cancer research and patient care. The company has developed a data platform that integrates and organizes clinical and financial information from electronic medical records and billing systems. This platform, known as OncologyCloud, provides valuable analytics for cancer care providers and life sciences organizations, enabling them to track treatment patterns, monitor adherence to guidelines, and identify suitable candidates for clinical trials in real-time. Flatiron Health also offers additional tools such as OncoCloud for community oncology practices, Flatiron Assist for clinical decision support, and OncoEMR to assist providers in meeting oncology care model requirements. The company collaborates with over 280 community cancer practices, several major academic research centers, and prominent oncology companies. Founded in 2012 and based in New York, Flatiron Health operates as a subsidiary of Roche Holding AG.

Pandion Operations, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for autoimmune diseases. Its lead product candidate, PT101, is an engineered variant of interleukin-2 (IL-2) currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions. Other product candidates include PT627, a systemic PD-1 agonist in preclinical studies; PT001, a bifunctional molecule designed to achieve tissue-selective immunomodulation in the gastrointestinal tract; and PT002, which combines an IL-2 mutein with a tether module for similar localized effects. The company collaborates with Astellas Pharma Inc. to develop immunomodulators aimed at autoimmune diseases specifically affecting the pancreas. Headquartered in Watertown, Massachusetts, Pandion Operations seeks to create innovative therapies that can provide durable and tissue-specific treatment options for patients suffering from these conditions.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company established in 2018 and based in South San Francisco, California. The company specializes in developing novel therapeutics aimed at addressing unmet medical needs in viral and liver diseases. Its lead candidate, ALG-010133, is a synthetic oligonucleotide currently undergoing Phase I clinical trials for chronic hepatitis B (CHB). In addition to this, Aligos is advancing several other drug candidates, including ALG-000184, a capsid assembly modulator for CHB; ALG-020572, an oligonucleotide for CHB; ALG-125097, an siRNA drug candidate for CHB; and ALG-055009, a small molecule THR-ß agonist targeting non-alcoholic steatohepatitis (NASH). The company leverages its extensive expertise in liver disease and viral hepatitis to develop targeted antiviral therapies, positioning itself as a leader in this therapeutic area.

Ignyta is a scientifically-driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goal is to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide. Ignyta was incorporated in 2011 and operates in San Diego, California.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

Viewics, Inc. offers Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare industry in the United States and Canada. The company provides the Viewics Data Platform, which integrates with various enterprise systems and supports multiple data formats for efficient data management. Among its key products are Viewics Health Insighter, which delivers interactive dashboards for clinical, operational, sales, and marketing teams, and Viewics Pulse, a web-based platform designed for data transparency and sharing among clients, patients, payors, and providers. These solutions facilitate operational insights, financial management, and compliance analytics, among other applications, and are utilized by a range of healthcare organizations, including clinical laboratories and hospitals. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

mySugr is a digital health company that simplifies life with diabetes. The mySugr App, in combination with integrated medical devices, empowers people with diabetes through a comprehensive self-management package: it includes the mySugr App (Logbook, Insulin Calculator, Diabetes Coach, Doctor Reports) and a connected blood sugar meter with home-delivered unlimited test strips. A large part of the company lives with diabetes, many since childhood.

Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through a partnership with the Fundacion para la Investigacion Medica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

ForSight VISION4 develops PDS to facilitate a wide array of molecules and therapeutic payloads, including the delivery of small molecules that have a short retention time inside the eye. The company was founded in 2009 by Eugene de Juan Jr. and is headquartered in Menlo Park, California.

Tioma Therapeutics, Inc. operates as an immuno-oncology company that develops anti-CD47 antibodies for the treatment of solid and hematologic cancers. Tioma Therapeutics, Inc. was formerly known as Vasculox, Inc. and changed its name to Tioma Therapeutics, Inc. in August 2016. The company was founded in 2006 and is based in St. Louis, Missouri with a corporate office in Brisbane, California.

Viewics, Inc. offers Software as a Service (SaaS) business intelligence and analytics solutions tailored for the healthcare industry in the United States and Canada. The company provides the Viewics Data Platform, which integrates with various enterprise systems and supports multiple data formats for efficient data management. Among its key products are Viewics Health Insighter, which delivers interactive dashboards for clinical, operational, sales, and marketing teams, and Viewics Pulse, a web-based platform designed for data transparency and sharing among clients, patients, payors, and providers. These solutions facilitate operational insights, financial management, and compliance analytics, among other applications, and are utilized by a range of healthcare organizations, including clinical laboratories and hospitals. Established in 2010 and based in Sunnyvale, California, Viewics operates as a subsidiary of Roche Holding AG.

Fabric Genomics is making genomics-driven precision medicine a reality. We provide clinical decision support software that enables clinical labs, hospital systems and country-sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabric’s end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology. Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics.

Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Our proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, our technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Our Ionic Purification System and Kits combine to provide researchers with a fast, efficient and effective alternative for automated nucleic acid purification.

Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.

Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.

MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders. The company‟s programs are based on the discovery from the laboratory of Dr. James Bradner at Dana-Farber Cancer Institute of first-in-class, potent small molecule BET bromodomain inhibitors. The company‟s lead program is aimed at the treatment of patients with BRD4-NUT midline carcinoma, acute myeloid leukemias, multiple myeloma, and other diseases. Tensha is a Focused Company funded by HealthCare Ventures.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Flatiron Health, Inc. is a healthcare technology company that specializes in oncology, focusing on enhancing cancer research and patient care. The company has developed a data platform that integrates and organizes clinical and financial information from electronic medical records and billing systems. This platform, known as OncologyCloud, provides valuable analytics for cancer care providers and life sciences organizations, enabling them to track treatment patterns, monitor adherence to guidelines, and identify suitable candidates for clinical trials in real-time. Flatiron Health also offers additional tools such as OncoCloud for community oncology practices, Flatiron Assist for clinical decision support, and OncoEMR to assist providers in meeting oncology care model requirements. The company collaborates with over 280 community cancer practices, several major academic research centers, and prominent oncology companies. Founded in 2012 and based in New York, Flatiron Health operates as a subsidiary of Roche Holding AG.

Atterocor, Inc. focuses on research and development of therapeutics for adrenal disease. Atterocor, Inc. was incorporated in 2012 and is based in Ann Arbor, Michigan.

They are constantly evolving better science by applying the latest advances in genomics and synthetic biology to help reduce costs, simplify workflows and improve results. Their core protein engineering technologies enable us to tailor enzymes to suit specific applications in next-generation DNA and RNA sequencing, DNA amplification and molecular diagnostics. Biomedical research is no longer limited by the constraints of native enzyme structure or function.

MacuLogix, Inc. specializes in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company offers the AdaptDx, a fully automated dark adaptometer designed to aid eye care professionals in detecting and tracking AMD at its earliest stages, potentially up to three years before it becomes visible. This early detection capability allows for timely intervention, which can help prevent vision loss. MacuLogix markets its products through distributors in the United States and internationally, as well as online, to ensure accessibility for healthcare providers. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix is committed to leveraging the science of dark adaptation to combat preventable blindness associated with AMD.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Adheron Therapeutics was established in 2006 as Synovex Corporation. The company’s therapeutic program is based on pioneering work done in the laboratory of Dr. Michael Brenner at Brigham and Women’s Hospital and Harvard Medical School. Dr. Brenner discovered that Cadherin-11 (Cad-11) acts as an “adhesive’ between cells and hanges in these Cad-11 interactions can induce the cells to produce many proteins that influence the cellular environment positively or adversely. Based on this discovery, Adheron is developing a best-in-class antibody tackling a variety of diseases by disrupting the adhesion of cells.

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

GeneWeave Biosciences is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles™ technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.

Vaxcyte, formerly known as SutroVax, is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks of vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).

Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.

mySugr is a digital health company that simplifies life with diabetes. The mySugr App, in combination with integrated medical devices, empowers people with diabetes through a comprehensive self-management package: it includes the mySugr App (Logbook, Insulin Calculator, Diabetes Coach, Doctor Reports) and a connected blood sugar meter with home-delivered unlimited test strips. A large part of the company lives with diabetes, many since childhood.

Zikani Therapeutics are among the most widely used, most effective, and safest antibiotics to reach clinical practice; in fact, azithromycin has been among the world’s most widely used antibiotics for the past several years. But, while current macrolides are highly effective against some major bacteria, they are ineffective against others, especially gram-negative bacteria, the cause of most serious infections in the US. The first three generations of macrolides have very limited activity against gram-negative, and the sole drug in the current fourth-generation, solithromycin, has only slightly greater activity. Within other antibiotic classes, a limited number of compounds are in development to treat resistant gram-negative infections, and even fewer are available both intravenously and orally, as would be expected with macrolides. The company was founded in 2014 and is headquartered in Newton, Massachusetts.

Signature Diagnostics GmbH is a translational oncology and genomics company based in Potsdam, Germany, founded in 2004. The company focuses on developing extensive tumor tissue and blood plasma biobanks for various cancers, including colorectal and lung cancer, through multicenter prospective clinical studies. A significant aspect of its work involves creating biobanks with longitudinal plasma samples from cancer patients, which aids in research and treatment monitoring. Additionally, Signature develops a range of next-generation sequencing assays using targeted gene panels and has expertise in ultra-deep sequencing tests utilizing circulating free DNA (cfDNA). This innovative approach may enhance non-invasive monitoring of treatment responses in cancer patients.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Established in 2011 and based in Cambridge, Massachusetts, the company utilizes its expertise in lysosome-based genetic disorders to create innovative treatment options. It specifically targets conditions such as Gaucher-related neurodegeneration and Parkinson’s disease, along with other synucleinopathies. Through its research and development efforts, Lysosomal Therapeutics aims to provide new solutions for patients suffering from these challenging neurological conditions.

Trophos is a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. Trophos is a fully integrated clinical stage company with a pipeline of original molecules in development for the motoneuron diseases amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and spinal muscular atrophy (SMA), chemotherapy-induced peripheral neuropathy, cardiac ischemia-reperfusion injury and other neurological conditions.

Foundation Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in molecular information products that analyze cancer specimens to provide genomic insights for personalized treatment. The company's platform employs proprietary methods to assist physicians in optimizing cancer therapies and supports biopharmaceutical companies in developing targeted treatments and immunotherapies. Its clinical products include FoundationOne for solid tumors, FoundationOne Heme for blood cancers, and several diagnostic assays aimed at specific cancer types, such as Foundation Assay for Circulating Tumor and FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine offers FoundationCORE, a knowledgebase that promotes advancements in oncology. The company engages in strategic collaborations with notable organizations, including F. Hoffmann-La Roche Ltd. and Genentech, to enhance precision medicine and develop companion diagnostics. Founded in 2009, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc.

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Bina Technologies focuses on enhancing personalized healthcare through advanced data analytics. The company has developed a big data science platform that provides scalable genomic analytics tailored for researchers and clinicians. This platform enables centralized management and processing of next-generation sequencing (NGS) data, facilitating insights for both academic and translational research. By significantly reducing the time, cost, and complexity involved in extracting knowledge from genomic data, Bina Technologies aims to transform the landscape of medicine and support the future of data-driven healthcare.

Dutalys is a privately owned antibody technology company based in Vienna, Austria. Dutalys was founded in April 2010 and supported by Seed financing from aws (Austria Wirtschaftsservice / ERP-Funds), by research grants from FFG (the Austrian Research Promotion Agency) and ZIT (the Technology Agency of the City of Vienna), and by funding from INiTS (the Austrian Academic Business Incubator).

Ariosa Diagnostics, Inc. (formerly Aria Diagnostics (formerly known as Tandem Diagnostics)), a San Jose, Calif.-based molecular diagnostics company.

Curetis AG focuses on multiparameter testing of many analytes in a single run, providing broad panels of combined pathogen and resistance gene detection for a wide range of diseases. Curetis integrates today´s molecular diagnostics laboratory into one instrument for the detection of severe bacterial infections as a first target application. However, the universal platform will also allow the future expansion into other clinical applications with additional market opportunities beyond infectious diseases.

Aileron Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing a novel class of drugs known as stabilized cell-permeating alpha-helical peptides, particularly in the field of oncology. The company’s lead drug candidate, ALRN-6924, is currently undergoing multiple clinical trials, including Phase 2a studies for advanced solid tumors and peripheral T-cell lymphoma, as well as Phase 1 trials for acute myeloid leukemia and advanced myelodysplastic syndrome. Aileron is also working on a next-generation wild type p53 reactivator. Collaborations with notable institutions, such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer, further enhance its research efforts, particularly in evaluating ALRN-6924 in combination therapies. Aileron Therapeutics was founded in 2001, originally named Renegade Therapeutics, and is headquartered in Watertown, Massachusetts.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

Allakos Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, founded in 2012. The company specializes in developing antibody-based therapeutics aimed at treating various diseases linked to dysregulation of the T-helper type 2 immune response, including allergic diseases, inflammation, and conditions characterized by excessive inflammatory cell production. Its lead therapeutic candidate, antolimab (AK002), targets conditions such as eosinophilic gastritis, eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Additionally, Allakos is advancing another program, AK006, which targets the Siglec-6 receptor on mast cells to modulate their activity and reduce excessive activation. Through these initiatives, Allakos aims to address significant unmet medical needs in immunological health.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, that specializes in developing sensitive tests for identifying and molecularly characterizing circulating tumor cells (CTCs) from minimally invasive blood samples. The company utilizes a platform that profiles single-cell phenotype and genotype, offering insights into phenotypic measures, specific biomarker expression levels, subcellular biomarker localization, and morphologic characteristics. Additionally, Epic Sciences provides the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer and offers solutions for biopharmaceutical companies. The company collaborates with various biotechnology and pharmaceutical firms, as well as major cancer centers and research institutions, to enhance cancer management and guide personalized medicine. Founded in 2008, Epic Sciences is dedicated to improving access to real-time biopsy material for better patient outcomes.

As the genomics community pushes toward the $1,000 genome, Genia is looking beyond, to the $100 genome, bringing the benefits of genome sequencing out of the lab and into the everyday world. Genia's technology is based on Biological Nanopores: Structure-Based Sequencing of Single DNA Molecules. We aim to reduce the price of sequencing and increase speed, accuracy, and sensitivity by moving away from amplification, complicated fluidics, and optical detection. Genia Technologies, Inc. is a private company located in Mountain View, CA. Genia was founded in March, 2009. The company recently closed its Series A round with a publicly held global biotech company.

Stratos Genomics, Inc., a DNA sequencing technology company, develops sequencing by expansion, a single-molecule detection process for genome sequencing and targeted oncology panels. It enables genome sequencing using nanopore technology, wherein a device transits through the nanopore and a distinct electrical signal of each base reporter is identified. The company was founded in 2007 and is based in Seattle, Washington. As of May 20, 2020, Stratos Genomics, Inc. operates as a subsidiary of Roche Holding AG.

Lysosomal Therapeutics, Inc. is a biotechnology company focused on discovering and developing small-molecule therapies for severe neurological diseases. Established in 2011 and based in Cambridge, Massachusetts, the company utilizes its expertise in lysosome-based genetic disorders to create innovative treatment options. It specifically targets conditions such as Gaucher-related neurodegeneration and Parkinson’s disease, along with other synucleinopathies. Through its research and development efforts, Lysosomal Therapeutics aims to provide new solutions for patients suffering from these challenging neurological conditions.

Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ). This complementary group of platform technologies has the potential to generate a number of distinct therapeutic products to treat a variety of serious viral infections such as chronic hepatitis B and C, HIV infection, and respiratory viruses (e.g. pandemic influenza) and emerging viral diseases (e.g. SARS).

Founded in 1998 in the Boston metropolitan area, IQuum is an early stage company dedicated to further developing there unique platform that will improve the extraction of information from biological samples. The platform will deliver the recent achievements in genomics and biotechnology to healthcare and daily life. IQuum has developed the novel lab-in-a-tube platform. The platform incorporates a closed sample tube, modular sample processor architecture and the latest biotechnology to provide a uniform system for cellular, protein, and nucleic acid tests. Our system enables rapid and ease-to-use biological sample testing, and performs multiple biological assays in an "insert-and-test" format, integrating all stages of sample processing -- from sample collection to result interpretation. The Company believes that this platform will meet the market needs for extracting comprehensive information from biological samples, and is developing the next generation of biological sample testing systems based on this platform.

MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.